论文部分内容阅读
背景:目前对于高血压凝血和纤溶系统的改变存在着争议,而凝血和纤溶系统在高血压血栓栓塞性和/或出血性并发症的进程中具有关键性作用,因此,检测高血压患者的凝血和纤溶状态,并以此为依据合理选用能改善其凝血和纤溶状态的抗高血压药以及据此提出合理的康复介入方案,具有不容忽视的临床价值。设计:随机对照的实验研究。目的:探讨厄贝沙坦和咪达普利在降压的同时,对早期雄性自发性高血压大鼠(spontaneouslyhypertensiverats,SHR)血浆凝血酶原时间、纤维蛋白原含量、组织型纤溶酶原激活物活性(tissue-typeplasminogenacti-vatoractivity,t-PA:A)、纤溶酶原激活物抑制剂活性(plasminogenactiva-torinhibitoractivity,PAI:A)和α2-纤溶酶抑制物活性(α2plasminin-hibitoractivity,α2-PI:A)的影响。地点、材料和干预:本实验在武汉大学医院检验中心进行。15周龄雄性SHR30只按随机数字表法分为3组,咪达普利组给予含咪达普利的水3mg/(kg·d);厄贝沙坦组给含厄贝沙坦的水50mg/(kg·d);SHR对照组和同龄雄性WistarKyoto(WKY)大鼠(正常血压对照组)10只以等量蒸馏水代替;采用一期法检测血浆凝血酶原时间,采用凝血酶法检测血浆纤维蛋白原含量,采用发色底物法检测血浆t-PA:A,PAI:A和α2-PI:A。主要观察指标:厄贝沙坦和
BACKGROUND: Currently there is controversy over changes in the coagulation and fibrinolysis systems of hypertension, and the coagulation and fibrinolytic systems play a key role in the progression of hypertensive thromboembolic and / or hemorrhagic complications. Therefore, Coagulation and fibrinolysis, and based on this, the rational selection of anti-hypertensive drugs that can improve their blood coagulation and fibrinolytic state and the reasonable rehabilitation intervention plan accordingly have clinical value that can not be ignored. Design: Randomized controlled experimental study. Objective: To investigate the effects of irbesartan and imidapril on the plasma prothrombin time, fibrinogen content, tissue plasminogen activator in spontaneously hypertypertensive rats (SHR) The activity of tissue-type plasminogenacti-vatoractivity (t-PA: A), plasminogen activator inhibitor activity (PAI: A) and α2plasminin-hibitoractivity PI: A). Location, Materials and Interventions: This experiment was conducted at the Wuhan University Hospital Examination Center. 15-week-old male SHR30 were divided into 3 groups according to the random number table method, 3 mg / (kg · d) of water with Imidapril in the Imidapril group, Irbesartan group 50 mg / (kg · d); 10 rats in SHR control group and Wistar male rats (normal blood pressure control group) of same age were replaced by equal volume of distilled water; Plasma fibrinogen content, the use of chromogenic substrate method for the detection of plasma t-PA: A, PAI: A and α2-PI: A. MAIN OUTCOME MEASURES: Irbesartan and